Oh Charlie, – “Current Infectious Diseases Society of America Recommendations:
Recommendation 1. Among patients who have been admitted to the hospital with COVID-19, the IDSA guideline panel recommends hydroxychloroquine/chloroquine in the context of a clinical trial”
For a Researcher – It sure took you a LONG Time to find this Recommendation!
BTW, my post was based on the American Thoracic Soceity Guideline.
Since it takes you SO LONG to find guidelines – I quoted it HERE:
“For hospitalized patients with COVID‐19 who have evidence of
pneumonia, we suggest hydroxychloroquine (or chloroquine) on a case‐by‐case basis.
Requirements include all of the following: a) shared decision‐making
in which the patient is informed about the possible benefits and
potential side effects, b) collection of data in a manner that enables studies that use valid methods for
causal inference and control of confounders for the purpose of interim assessment, c) the patient’s
clinical condition is sufficiently severe to warrant investigational therapy, and d) there is not a shortage of drug supply”